Farxiga

Chemical Namedapagliflozin
Dosage FormTablet (oral; 5 mg, 10 mg)
Drug ClassInhibitors
SystemEndocrine
CompanyAstraZeneca
Approval Year2014

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.
  • Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (NYHA class II-IV).
  • Indicated to reduce the risk of sustained eGFR decline, end stage kidney disease cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
Last updated on 7/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Farxiga (dapagliflozin) Prescribing Information.2022AstraZeneca Pharmaceuticals LP Wilmington, DE
Document TitleYearSource
Dapagliflozin for non-alcoholic fatty liver disease: a systematic review and meta-analysis.2022Diabetes Research and Clinical Practice
Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: a systematic review and meta-analysis.2022Journal of Diabetes Research
Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis.2022Canadian Journal of Diabetes
Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials.2022Advances in Therapy
Comparative efficacy of five SGLT2i on cardiorenal events: a network meta-analysis based on ten CVOTs.2022American Journal of Cardiovascular Drugs
Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.2022Journal of Cardiovascular Pharmacology
Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials.2022European Heart Journal: Quality of Care and Clinical Outcomes
Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.2022Clinics and Research in Hepatology and Gastroenterology
Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: a meta-analysis.2022Journal of Cellular and Molecular Medicine
The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/ heart failure: a systematic review and meta-analysis.2022Journal of Thoracic Disease
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. 2021Heart Failure Reviews
High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: a meta-analysis of randomized clinical trials.2021Diabetes, Obesity & Metabolism
Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials.2021Heart Rhythm
Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. 2021Medicine
Microvascular benefits of new antidiabetic agents: a systematic review and network meta-analysis of kidney outcomes.2021Journal of Clinical Endocrinology & Metabolism
Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis.2021Cardiovascular Drugs and Therapy
Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.2021Oman Medical Journal
Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: a systematic review and meta-analysis.2021IJC Heart & Vasculature
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis.2020Annals of Internal Medicine
Peripheral artery disease and amputations with sodium-glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized controlled trials.2019Diabetes Research and Clinical Practice